Cover Image
市場調查報告書

原癌基因RAF 絲胺酸/蘇氨酸蛋白激酶:開發中產品分析

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365757
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
原癌基因RAF 絲胺酸/蘇氨酸蛋白激酶:開發中產品分析 RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 53 Pages
簡介

本報告提供以原癌基因RAF 絲胺酸/蘇氨酸蛋白激酶為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

原癌基因RAF 絲胺酸/蘇氨酸蛋白激酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Basilea Pharmaceutica AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Redx Pharma Plc
  • Sirnaomics, Inc.
  • VG Life Sciences, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1001TDB

Summary:

According to the recently published report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

The report 'RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H2 2017' outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 6, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Breast Cancer, Metastatic Melanoma, Pancreatic Cancer, Bladder Cancer, Colon Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Adenocarcinoma, Metastatic Ovarian Cancer, Multiple Myeloma (Kahler Disease) and Sarcomas.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
    • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Amitech Therapeutic Solutions Inc
    • Basilea Pharmaceutica Ltd
    • CBT Pharmaceuticals Inc
    • Chugai Pharmaceutical Co Ltd
    • Hanmi Pharmaceuticals Co Ltd
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Redx Pharma Plc
    • VG Life Sciences Inc
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
    • BAL-3833 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBT-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCBCI-0902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FYA-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-95573 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxychloroquine + sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXH-254 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REDX-05358 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit B-RAF and C-RAF for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor
      • Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium
      • Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO
      • Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting
      • Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting
      • Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
      • Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment
      • Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study
      • Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study
      • Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study
      • Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association;
      • Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study
      • Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine
      • Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib
      • Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amitech Therapeutic Solutions Inc, H2 2017
  • Pipeline by Basilea Pharmaceutica Ltd, H2 2017
  • Pipeline by CBT Pharmaceuticals Inc, H2 2017
  • Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
  • Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Redx Pharma Plc, H2 2017
  • Pipeline by VG Life Sciences Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administrations, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top